All In Biotech

Drug Trial Radar · NCT03401112

A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)

A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)

Last checked: Nov 20, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

100

Actual

Start

Jan 26, 2018

Primary completion

Aug 28, 2020

Study completion Aug 28, 2020

Sponsor

Sponsor type
Industry
Collaborators
Imara, Inc.
First posted
Jan 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study of IMR-687 in adult participants with sickle cell anemia (SCA) (homozygous HbSS or sickle-β0 thalassemia).

Conditions

  • Sickle Cell Disease

Interventions

  • IMR-687Drug

    Oral administration of IMR-687 once daily with or without HU.

  • PlaceboDrug

    Oral administration of placebo once daily with or without HU.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number Of Participants With Treatment-emergent Adverse Events (TEAEs) And Serious Adverse Events (SAEs)Time frame: Day 1 (after dosing) through up to Week 24

Locations

13 sites in 2 countries. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • University of Connecticut Health Center

    Farmington, Connecticut

  • Foundation for Sickle Cell Disease Research

    Hollywood, Florida

  • University of Illinois

    Chicago, Illinois

  • Loretto Hospital

    Chicago, Illinois

  • Medical University of South Carolina

    Charleston, South Carolina

  • Baylor Scott & White Health

    Temple, Texas

  • Sandwell & West Birmingham Hospital

    Birmingham, United Kingdom

  • Bristol Haematology and Oncology Centre

    Bristol, United Kingdom

  • Royal London Hospital

    London, United Kingdom

  • University College London Hospital

    London, United Kingdom

  • Guy's Hospital

    London, United Kingdom

  • Oxford Cancer & Haematology Centre, The Churchill Hospital

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.